The Inhibition of Heat Shock Protein 90 Facilitates the Degradation of Poly-Alanine Expanded Poly (A) Binding Protein Nuclear 1 via the Carboxyl Terminus of Heat Shock Protein 70-Interacting Protein

Abstract

BackgroundSince the identification of poly-alanine expanded poly(A) binding protein nuclear 1 (PABPN1) as the genetic cause of oculopharyngeal muscular dystrophy (OPMD), considerable progress has been made in our understanding of the pathogenesis of the disease. However, the molecular mechanisms that regulate the onset and progression of the disease remain unclear.ResultsIn this study, we show that PABPN1 interacts with and is stabilized by heat shock protein 90 (HSP90). Treatment with the HSP90 inhibitor 17-AAG disrupted the interaction of mutant PABPN1 with HSP90 and reduced the formation of intranuclear inclusions (INIs). Furthermore, mutant PABPN1 was preferentially degraded in the presence of 17-AAG compared with wild-type PABPN1 in vitro and in vivo. The effect of 17-AAG was mediated through an increase in the interaction of PABPN1 with the carboxyl terminus of heat shock protein 70-interacting protein (CHIP). The overexpression of CHIP suppressed the aggregation of mutant PABPN1 in transfected cells.ConclusionsOur results demonstrate that the HSP90 molecular chaperone system plays a crucial role in the selective elimination of abnormal PABPN1 proteins and also suggest a potential therapeutic application of the HSP90 inhibitor 17-AAG for the treatment of OPMD.

Arl13b Promotes Gastric Tumorigenesis by Regulating Smo Trafficking and Activation of the Hedgehog Signaling Pathway

“…The reaction was incubated with 50 μl of 1:1 slurry beads conjugated with protein G or A (Roche) for 3 hr at 4°C. Beads were washed 4 times with lysis buffer before the addition of SDS sample buffer and subjected to WB analysis as described previously (26). …”

Protective mechanism of SIRT1 on Hcy‐induced atrial fibrosis mediated by TRPC3

“…Pre-cleared cell lysates were incubated with equal amounts of primary antibodies (2-5 μL) or IgG at 4°C before performing the pull-down with 50 μL of 1:1 Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, sc-2003) for 2 hours. Beads were washed four times with lysis buffer, boiled and elution collected for WB analysis 18,19.…”

Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development

“…This was observed in a mouse model of the polyQ expansion disease spino bulbar muscular atrophy (SBMA), which upon treatment with 17-AAG or its oral form 17-DMAG presented reduced motorneuron degeneration and significant improvements in locomotor function (Tokui et al, 2009;Waza et al, 2005). Similarly, treatment with 17-AAG in a mouse model of the polyA expansion disease oculopharyngeal muscular dystrophy (OPMD) promoted degradation of the toxic protein by the UPS, reduced aggregate formation and increased in vitro and in vivo cell survival (Shi et al, 2015). Similar results have also been obtained in the field of amyloid diseases, supporting the idea that pharmacological UPR activation has a strong therapeutic potential for aggregating protein diseases (Ryno et al, 2013), and could be on this basis very useful against FMRpolyG toxicity.…”